Core Viewpoint - MediPharm Labs Corp. is set to release its full year and fourth quarter financial results for the period ending December 31, 2025, on March 30, 2026, before market opening [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and webcast scheduled for March 30, 2026, at 10:00 a.m. Eastern time [2] - Participants are encouraged to join the call approximately 15 minutes early [3] Group 2: Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients [5] - The company operates a Good Manufacturing Practices certified facility with ISO standard-built clean rooms [5] - MediPharm Labs has invested in advanced technology and methodologies for the delivery of precision-dosed cannabis products [5] Group 3: Regulatory and Market Position - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale domestic GMP License for extracting multiple natural cannabinoids [6] - The company is currently pursuing foreign drug manufacturing site registration with the US FDA [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

Core Viewpoint - MediPharm Labs Corp. announces the resignation of CEO David Pidduck, effective January 23, 2026, with CFO Greg Hunter appointed as Interim CEO while the Board evaluates long-term leadership plans [1][2]. Group 1: Leadership Transition - David Pidduck has been instrumental in stabilizing and repositioning the company, successfully executing restructuring initiatives and improving profitability [2]. - Greg Hunter, appointed as Interim CEO, has a strong background in financial management and has implemented cost-reduction initiatives, enhancing financial and operational controls since becoming CFO in February 2021 [3][4]. - The Board expresses confidence in Hunter's ability to drive execution and operational discipline during this transition period [5]. Group 2: Company Background - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and advanced derivative products in a GMP-certified facility [6]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale, domestic GMP license for extracting multiple natural cannabinoids [7]. - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to Canadian medical patients and enhancing its international operations [8].

Core Viewpoint - The reclassification of cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act is a significant milestone that recognizes its medical use and is expected to facilitate clinical research and partnerships for MediPharm Labs [1][4][10]. Industry Impact - The reclassification is anticipated to accelerate cannabis-related medical research by removing barriers that have historically limited U.S. clinical trials, allowing for standardized medical-grade cannabis access [4][5]. - The change may lead to increased interest from institutional investors in research-oriented cannabis companies, as regulatory barriers evolve [10]. Company Positioning - MediPharm Labs is strategically positioned to benefit from this reclassification due to its FDA site registration, Drug Establishment License, and experience in supplying clinical trial materials to the U.S. [2][6]. - The company has a proven track record, having supplied products for over 10 active clinical trials, including significant studies funded by the U.S. National Institutes of Health [7][8]. Research and Development Opportunities - The reclassification is expected to create a pipeline of researchers ready to advance clinical trials and evaluate compliant active pharmaceutical ingredient suppliers [5]. - MediPharm Labs has developed international licensing and regulatory expertise, enabling it to support new research initiatives that require pharmaceutical-grade standards [6][9]. Future Growth Potential - The company anticipates that the reclassification will strengthen its ability to expand U.S. clinical trial partnerships and facilitate significant growth in clinical research [3][10]. - MediPharm Labs' unique combination of experience and regulatory credentials positions it to immediately support new research initiatives in the U.S. and globally [8][9].

Core Insights - The urgency of addressing pharmaceutical supply chains is highlighted, particularly the reliance of the US on China for essential drug ingredients [1][12] - The US-China Economic and Security Review Commission has proposed legislative changes to enhance FDA authority over pharmaceutical supply chain transparency [1][12] Industry Dependence - The US heavily depends on China for foundational ingredients in medicines, with China producing a significant share of key starting materials (KSM) and active pharmaceutical ingredients (API) [1][6] - In 1980, China was not a significant player in drug master files submitted to the FDA, but by last year, it accounted for 45% of total filings, surpassing India [6][16] - Approximately half of the active ingredients used in the US originate from China, which is the sole supplier of at least one chemical in nearly 700 essential medicines [9][16] Supply Chain Risks - The COVID-19 pandemic underscored the risks of over-reliance on a single source for medical supplies, particularly from a geopolitical rival [11][16] - The potential for future global health crises poses additional threats to the stability of the pharmaceutical supply chain [11][16] Strategic Initiatives - There is a push to develop a supply chain involving India and other allies to reduce dependence on China, although this presents challenges due to low profit margins in the production of starting compounds [12][13] - The US may need to implement measures similar to the Pentagon's agreement with MP Materials Corp. to stabilize the supply chain for critical medicines [14][16]

Core Insights - Eli Lilly and Company (LLY) plans to invest $5 billion in a new manufacturing facility in Virginia, driven by the Trump administration's push for increased domestic production [1] - The facility is expected to create approximately 650 high-paying manufacturing jobs and 1,800 construction jobs, focusing on active pharmaceutical ingredients (API) and antibody-drug conjugates (ADCs) [2] - This Virginia site is part of Lilly's broader commitment to invest $27 billion in four new manufacturing sites in the U.S. by 2025, contributing to over $50 billion in domestic manufacturing expansion since 2020 [3] Investment and Manufacturing Trends - The U.S. pharmaceutical industry is responding to potential tariffs on imports, with companies like Lilly, J&J, AstraZeneca, GSK, Novartis, and Roche announcing significant investments to boost U.S. manufacturing [5][9] - GSK plans to invest $30 billion in R&D and supply chain infrastructure in the U.S. over the next five years, while AstraZeneca has committed $50 billion by 2030 [6] - J&J announced over $55 billion in investments for U.S. manufacturing and R&D over the next four years, and Roche plans to invest $50 billion, creating over 12,000 jobs [7] Challenges and Market Dynamics - The shift to U.S. production may lead to higher drug prices for consumers due to increased production costs, impacting profit margins for drugmakers [10] - Companies may still rely on international markets for cheaper drugs and key ingredients, necessitating additional incentives like tax breaks and subsidies to encourage domestic production [11] - Lilly's stock has seen a decline of 1.0% this year, compared to a 0.7% decrease in the industry, with its price/earnings ratio at 26.63, significantly higher than the industry average of 14.69 [12][13]

Core Points - Eli Lilly and Company plans to build a $5 billion manufacturing facility in Goochland County, Virginia, focusing on active pharmaceutical ingredients (API) for cancer and autoimmune therapies [1][2] - The facility will create 2,450 high-wage jobs, including 650 manufacturing positions and 1,800 construction jobs, contributing significantly to the local economy [4][5] - This site is the first of four new U.S. manufacturing locations Lilly intends to announce this year as part of a broader $50 billion capital expansion commitment since 2020 [2][9] Company Commitment - The investment in Virginia highlights Lilly's commitment to U.S. innovation and manufacturing, aiming to strengthen the domestic supply chain and enhance the delivery of medicines [4][6] - Lilly plans to utilize advanced technologies such as machine learning and AI at the new facility to ensure efficient and safe production processes [6][8] - The company emphasizes sustainability and community engagement, planning to partner with local universities and support educational initiatives [6][8] Economic Impact - For every dollar invested in the Virginia facility, it is expected that up to four dollars will be generated in local economic activity [5] - Each manufacturing job created is projected to support multiple positions in related industries, such as supply chain and logistics [5] - The facility is anticipated to significantly benefit the local economy and strengthen Virginia's position in the pharmaceutical industry [6][8]

Core Points - MediPharm Labs Corp. held its annual and special meeting where key resolutions were voted on by shareholders [1][2] - A total of 210,726,733 common shares were represented, accounting for 50.76% of the total issued shares [2] - The meeting resulted in the approval of several resolutions including the number of directors, appointment of auditors, election of directors, and unallocated awards under the equity incentive plan [3] Voting Results - The resolution to fix the number of directors at seven was approved with 75.46% voting in favor [5] - All management director nominees were elected with Chris Halyk receiving 144,007,422 votes and Emily Jameson receiving 144,289,930 votes [6] - MNP LLP was appointed as the auditor with 90.78% of votes in favor [7] - The resolution for unallocated awards under the equity incentive plan was narrowly approved with 50.14% voting for and 49.86% against [8] Board Changes - New directors Emily Jameson and John Medland were welcomed to the Board, while Michael Bumby did not stand for re-election [4] Company Overview - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and advanced derivative products [9] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [10] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [11]

Core Viewpoint - MediPharm Labs Corp. is urging shareholders to be cautious regarding the election of three Dissident Nominees associated with Apollo Technology Capital Corporation, citing concerns over their past involvement with Check-Cap Ltd. and its governance issues [1][2][18]. Summary of Recent Events at Check-Cap - Check-Cap has faced significant governance challenges, including poor transparency, high turnover, and questionable cash resource allocation, leading to a decline in shareholder value [3][6]. - A notable incident involved Check-Cap transferring millions of dollars to Apollo and its subsidiaries, which raises concerns about the motives of the Dissident Nominees [4][11]. - The Check-Cap Board approved a $6 million loan to Nobul and transferred $11 million to a segregated account for Nobul's growth initiatives, despite no formal business combination being completed [8][9]. Connections to the Dissident Nominees - Three of the six Dissident Nominees for MediPharm's Board have been directly involved in Check-Cap's governance issues, raising questions about their qualifications to lead another public company [11][14]. - The involvement of these individuals in Check-Cap's tumultuous history suggests a potential risk for MediPharm shareholders [12][18]. Shareholder Voting Assistance - MediPharm encourages shareholders to vote using the GREEN proxy in support of the Company's nominees, emphasizing the importance of disregarding communications from the Dissident Nominees [19][20]. Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis products and has a GMP license from Health Canada, positioning it as a leader in the cannabinoid sector [21][23]. - The Company expanded its reach through the acquisition of VIVO Cannabis Inc., enhancing its presence in the medical cannabis market [24].